Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The applicability of a predictive index for second- and third-line treatment of unselected non-small-cell lung cancer patients.

Respiration; international review of thoracic diseases - 1 Jan 2011

Wojas-Krawczyk Kamila, Krawczyk Paweł, Mlak Radosław, Kucharczyk Tomasz, Kowalski Dariusz M, Krzakowski Maciej, Milanowski Janusz

Abstract excerpt

BACKGROUND: Tyrosine kinase inhibitors of EGFR (TKI-EGFR) induced response in only 10% of Caucasian non-small-cell lung cancer patients in second- or third-line treatment. Independent predictive factors for qualification to TKI-EGFR treatment have not been assessed. In 2008, a prognostic index wa...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Eruptions
Share to Erlotinib Hydrochloride

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lipoproteins, HDL

Share to Predictive Value of Tests

Share to Proportional Hazards Models

Share to Quinazolines

Share to Survival Analysis

Share to Weight Loss

Source

Identifiers

PMID: 21242665
DOI: 10.1159/000322843

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-21242665-2026-09-04.1. Manifest publication-graph-cohort-2026-09-04.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The applicability of a predictive index for second- and third-line treatment of unselected non-small-cell lung cancer patients.PMID 21242665Read ↗

Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene.Semantic proximity Read ↗

BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study.Semantic proximity Read ↗

Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study.Semantic proximity Read ↗

Development, internal validation and calibration of a risk score to predict survival in patients with EGFR-mutant non-small cell lung cancer.Semantic proximity Read ↗

The impact of clinical parameters on progression-free survival of non-small cell lung cancer patients harboring EGFR-mutations receiving first-line EGFR-tyrosine kinase inhibitors.Semantic proximity Read ↗

The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status.Semantic proximity Read ↗

Predictive factors for response and for resistance to tyrosine kinase inhibitor therapy in lung cancer.Semantic proximity Read ↗

Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed.Semantic proximity Read ↗

Predictors of sensitivity and resistance to epidermal growth factor receptor inhibitors.Semantic proximity Read ↗

Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials.Semantic proximity Read ↗

From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy.Semantic proximity Read ↗

Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.